Postpartum OCD vs Psychosis: Key Differences

On a day in 2020, CNN correspondent Pamela Brown boarded Air Force One as the reporter assigned to the press pool, the rotating group of journalists who travel with the president and file a report the rest of the press corps relies on. Her notes from that day read like any other day's work. Nothing in them hints that she was, in her words, almost paralyzed. She had a toddler, a newborn, a mother who had just died during the pandemic, and a brain that had started producing a horror movie on a loop: visions of dropping her baby down the stairs, of losing control of the car. She told no one, not even her husband (05:57).

What Brown was living through had a name she did not yet know: postpartum OCD, short for obsessive-compulsive disorder, a condition in which a thought gets stuck and the brain treats it as a threat that must be solved rather than a thought that can be let go. She describes the mechanism plainly.

"I just remember having, like, a really scary thought of, what if I drop my baby down the stairs? I developed postpartum OCD." (00:00) — Pamela Brown

What finally broke the loop was not a doctor but a search engine. Brown found an article by a researcher named Dr. Jordan Levy that described her symptoms almost word for word. She emailed him. He wrote back. He told her she needed exposure therapy, a structured way of facing a feared thought without performing the reassurance rituals that feed it, and the fog started to lift (07:36). The experience left her with a question that would not go away: how many other women were suffering like this with nowhere credible to turn?

That question became Body Language, an eight-episode CNN streaming series Brown created, with the first four episodes airing now and four more in November (09:13). The series covers the territory doctors often rush past in a fifteen-minute visit: perimenopause, GLP-1 weight-loss drugs, egg freezing, PCOS and PMOS (two metabolic conditions that affect ovulation), thyroid disease, breast reductions, the fourth trimester, and Alzheimer's disease. Brown's co-guide through much of this territory is Dr. Mary Claire Haver, a board-certified OB-GYN and certified menopause practitioner, who appeared in the pilot episode and joined her again here to unpack what the reporting turned up.

One throughline across the conversation is that exercise is not optional cosmetic maintenance, it is neurological insurance. Alzheimer's disease shows up far more often in women than in men (11:15), and when Brown asked one of the doctors she interviewed what single habit most protects against it, the answer was simple: never go more than a few days without moving (11:43). Haver has started framing workouts to her patients the same way, not as a path to a certain look but as a transaction with the future.

The Math Behind Weight-Loss Drugs and Muscle

GLP-1 drugs, the class that includes semaglutide and tirzepatide, have produced a side effect almost nobody saw coming: pregnancies. Obesity, irregular periods, and metabolic conditions like PCOS and PMOS all suppress fertility. When a GLP-1 drug repairs the underlying metabolic problem, fertility can return before a patient has adjusted her expectations, or her contraception (14:05). Haver now routinely asks GLP-1 patients in perimenopause what they are doing for birth control, because the drug's benefit can arrive as a surprise.

The other side effect worth planning for is muscle loss. Rapid weight loss without enough protein or resistance training strips lean mass along with fat, and Haver points to a framework from obesity physician Rocio Salas Weinryb that she calls non-negotiable: GLP-1, Protein, Strength training, or GPS (15:53). Skip the protein and the lifting, and the weight comes off along with the muscle and bone density a person will need decades later to stay independent.

The Parts of Medicine That Got Left Behind

Two gaps in women's health came up that illustrate how uneven the research base still is. The first is testosterone. There is no testosterone product approved by the FDA, the agency that regulates drugs in the United States, specifically for women (25:43). Haver prescribes it anyway, borrowing from the men's formulation and cutting the dose to about a tenth of a standard male pump, applied as a pea-sized amount to skin without hair follicles. She asks patients to commit to three months before judging the result, and to recheck hormone levels if nothing has changed by then (27:36). She is candid about the limits of the evidence and equally candid about where she lands on it.

"Lack of research does not mean... you must accept the patient's clinical experience and let her make a decision for herself." (27:23) — Dr. Mary Claire Haver

The second gap is more mundane and more consequential: a national shortage of estrogen patches. Patches are harder and less profitable to manufacture than pills, and demand jumped after the FDA removed a long-standing black box warning that had scared patients away from estrogen therapy (33:43). A coupon-assisted generic patch can run about $25 a month, while the gels and sprays many patients have switched to, none of which have a generic equivalent, often cost more than $100 a month (35:14). Haver has been part of a public letter-writing campaign to the FDA, which has since acknowledged working with pharmacies to increase supply.

Underneath both of these gaps sits a figure that deserves more attention than it gets: vaginal estrogen, applied locally rather than absorbed throughout the body, can prevent about half of urinary tract infections in postmenopausal women (35:52). Haver connects this directly to a more dangerous outcome. Among elderly women who arrive at the emergency room with a fractured hip, more than 65% already have a UTI at the time of diagnosis, and some clinicians suspect the resulting disorientation contributes to the fall itself (36:31). Her recommendation is blunt.

"The minute they're menopausal. They should just be on it prophylactically." (37:05) — Dr. Mary Claire Haver

The conversation closes where it began, with the difference between a thought a mother cannot stop having and a mind that has stopped tracking reality. Brown brings up the trial of Lindsey Clancy, a Massachusetts mother on trial in a case involving the deaths of her three children after what prosecutors and her defense both described as severe postpartum psychosis, a condition Haver connects historically to the 2001 case of Andrea Yates, who drowned her five children while in psychosis, hearing voices that told her the children needed saving from the devil (40:12). Both Brown and Haver want the distinction understood clearly, because conflating the two conditions keeps women like Brown silent out of fear.

"Intrusive thoughts does not make you any more harmful to anyone around you... Psychosis is you're entering a different reality." (42:59) — Pamela Brown

Brown also notes that many of Clancy's appointments were conducted over telehealth, raising the question of whether an in-person visit, one where a clinician could read her body language and feel her distress directly, might have changed the outcome (42:08). It is a fair question without a clean answer, and it sits uneasily next to the fact that telemedicine is also the reason many rural and overbooked women get any care at all.

What ties the hour together is not a single diagnosis or drug but a pattern: conditions that are common, sometimes life-threatening, and routinely under-discussed because the standard appointment is too short and the research base too thin. Brown turned her own period of silence into eight episodes of television. Haver turned a career of being undertrained in testosterone and vaginal estrogen into a practice built around naming what the data has not yet caught up to. Neither claims to have finished the job. Both seem to agree that the fix starts with saying the thing out loud.